𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevalence and risk factors for delayed adrenal insufficiency after liver transplantation

✍ Scribed by Pierluigi Toniutto; Carlo Fabris; Elisa Fumolo; Davide Bitetto; Ezio Fornasiere; Edmondo Falleti; Rachele Rapetti; Rosalba Minisini; Mario Pirisi


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
125 KB
Volume
14
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Liver transplantation (LT) recipients are at risk for early and delayed adrenal insufficiency for multiple reasons. Although early adrenal insufficiency is known to occur in a high proportion of recipients maintained on steroid-free immunosuppressive regimens, the prevalence and risk factors associated with delayed functional adrenal gland atrophy (FAGA) are unknown because routine evaluation for this condition is not standard practice among LT centers. We investigated a group of 87 patients (64 males) transplanted for end-stage liver disease related to different etiologies. All underwent a standard corticotropin stimulation test (CST) when, after gradual steroid tapering, they had been maintained for at least 1 week on oral prednisone at a daily dose of 5 mg. FAGA, defined by a serum cortisol concentration that, 60 minutes after corticotropin administration, did not double the baseline level and remained Ο½20 g/dL, was diagnosed in 23/87 patients (26.4%). Stepwise logistic regression analysis selected as significant predictors of FAGA the cumulative dosage of corticosteroids administered (P Ο½ 0.01), the increase in the body mass index after LT (P Ο½ 0.01), a low serum cholesterol concentration (P Ο­ 0.005), and a high adrenocorticotropin hormone (ACTH) serum level (P Ο½ 0.05) at the time CST was performed. In conclusion, FAGA is a common condition among LT recipients who are maintained on prolonged corticosteroid immunosuppressive treatment. Factors associated with FAGA include the cumulative steroid dose, weight changes after LT, and ACTH and cholesterol levels at the time of steroid withdrawal.


πŸ“œ SIMILAR VOLUMES


Cardiovascular risk factors after liver
✍ Santiago J. MuΓ±oz; Hisham ElGenaidi πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 72 KB

## Key Points 1. Yearly screening of liver recipients with serum cholesterol, triglycerides, and lipoproteins, and assessment for risk factors for atherosclerotic cardiovascular disease, is an important component of comprehensive post transplant care. 2. Revised guidelines and target levels of LDL-

Risk factors for recurrence of autoimmun
✍ Aldo J. Montano-Loza; Andrew L. Mason; Mang Ma; Ravin J. Bastiampillai; Vincent πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 196 KB πŸ‘ 1 views

Autoimmune hepatitis has been reported to recur after liver transplantation. The aim of our study was to evaluate the risk factors associated with recurrence of autoimmune hepatitis. Forty-six patients that underwent liver transplantation because of end-stage liver disease secondary to autoimmune he

Risk factors for recurrence of hepatitis
✍ Herrero, J. Ignacio ;PeΓ±a, AndrΓ©s de ;Quiroga, Jorge ;Sangro, Bruno ;Garcia, Nic πŸ“‚ Article πŸ“… 1998 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 97 KB πŸ‘ 2 views

Recurrent hepatitis C is a frequent complication after liver transplantation for hepatitis C virus-related cirrhosis, but risk factors related to its development remain ill defined. Twenty-three patients receiving a primary liver graft for hepatitis C virus-related cirrhosis and with an assessable b

Risk factors for recurrence of primary s
✍ Evangelos Cholongitas; Vibhakorn Shusang; George V. Papatheodoridis; Laura Marel πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

Liver transplantation (LT) is the only therapeutic option for end-stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation f

Risk factors for recurrence of primary s
✍ Jacob Alexander; James D. Lord; Matthew M. Yeh; Carlos Cuevas; Ramasamy Bakthava πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 123 KB πŸ‘ 2 views

Orthotopic liver transplantation (OLT) is the only effective treatment for end-stage liver disease due to primary sclerosing cholangitis (PSC). Recurrence of PSC has recently emerged as a leading cause of allograft failure in the long term. There is limited data on risk factors for recurrence of PSC